Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
2018-003119-22Phase 2Completed
- Sponsor
- ENYO Pharma
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing EYP001a with Placebo (2 arms). Primary endpoint: Change in liver fat content by MRI-PDFF. Started Feb 2019; status: completed.
02
Drugs
vonafexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2018-003119-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003119-22.